Overview

Dose Escalation Study of JNJ-54767414 (Daratumumab) in Chinese Participants With Relapsed or Refractory Multiple Myeloma Who Failed at Least 2 Prior Lines of Systemic Therapy

Status:
Completed
Trial end date:
2019-12-13
Target enrollment:
0
Participant gender:
All
Summary
The purpose of this study is to evaluate the tolerability, safety and the pharmacokinetic (PK) profile of daratumumab in Chinese participants with relapsed or refractory multiple myeloma (RRMM) who failed at least 2 prior lines of systemic therapy (Part 1 and Part 2); and to evaluate the tolerability and safety of daratumumab in Chinese participants whose prior therapy included a proteasome inhibitor (PI) and an immunomodulatory drug (IMiD) and who have demonstrated disease progression on the last therapy (Part 3).
Phase:
Phase 1
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Janssen Research & Development, LLC
Treatments:
Antibodies, Monoclonal
Daratumumab
Criteria
Inclusion Criteria:

Part 1 and 2:

- Chinese participant who must be at least 20 years of age

- Documented multiple myeloma (MM) with measurable disease according to protocol-defined
criteria

- Relapsed or refractory multiple myeloma after receiving at least 2 prior lines of
therapy

- Eastern Cooperative Oncology Group performance status score of 0, 1, or 2

- Adequate recovery from prior therapy

Part 3:

- Chinese participants who must be at least 18 years of age

- Received both a proteasome inhibitor (PI) (greater than or equal to [>=] 2 cycles or 2
months of treatment) and an immunomodulatory drug (IMiD) (>=2 cycles or 2 months of
treatment) in any order during the course of treatment (except for participants who
discontinued either of these treatments due to a severe allergic reaction within the
first 2 cycles/months)

- Documented evidence of progressive disease (PD) based on investigator's determination
of response as defined by the International Myeloma Working Group (IMWG) criteria on
or after their last regimen

Exclusion Criteria:

Part 1 and 2:

- Received daratumumab or other anti-CD38 therapies previously

- Previously received an allogenic stem cell transplant or has received an autologous
stem cell transplantation within 12 weeks

- Exhibiting clinical signs of meningeal involvement of multiple myeloma

- Known chronic obstructive pulmonary disease, known moderate or severe persistent
asthma within the past 2 years, or uncontrolled asthma of any classification

- Known clinically significant cardiac disease

- Known to be seropositive for human immunodeficiency virus, hepatitis B or known to
have a history of hepatitis C

- Has plasma cell leukemia, Waldenstrom's macroglobulinemia, POEMS syndrome
(polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes),
or amyloidosis

- Abnormal laboratory values according to protocol-defined parameters at screening

Part 3:

- Received anti-myeloma treatment within 2 weeks before Cycle 1, Day 1